Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.19 | 3e-07 |
mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-05 |
mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-05 |
mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.19 | 9e-05 |
mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0001 |
mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.48 | 0.0001 |
mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0002 |